Search

I am a physician-scientist specializing in gastrointestinal (GI) cancers, with a strong focus on the cancer-microbiome-immune axis. Trained in medical oncology at the University of Paris La Sorbonne and specialized in GI malignancies at the Curie Institute, France, I have led research exploring the role of intratumoral bacteria in tumor heterogeneity and immune modulation. My work has demonstrated that Fusobacterium nucleatum is a favorable prognostic factor in squamous cell carcinomas and linked microbial diversity to immune markers in cancer. I also investigate microbiota in metastases, collaborating with the French National Cancer Institute (INCa) and MSKCC to explore how targeting tumor-associated bacteria can enhance anticancer immune responses. At MSKCC, I lead research on mechanisms of resistance and response to combined PARP and PD-1 inhibition in pancreatic cancer, leveraging single-cell RNA sequencing and spatial proteomics. My expertise spans digital pathology, genomics, immunology, and bioinformatics, bridging translational science with clinical oncology to develop novel therapeutic strategies.

The study of some victims exposed to ionizing radiation from the 1986 Chernobyl nuclear power plant accident is yielding new information about how radiation-induced thyroid cancer develops.